{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-268154","form_type":"8-K","ticker":"LBRX","cik":"0001691082","company_name":"LB PHARMACEUTICALS INC","filed_at":"2025-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.157528+00:00","generated_at":"2026-05-16T23:48:42.069747+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"LB Pharmaceuticals Reports Q3 2025 Results and Provides Trial Updates","bullets":["Net loss narrowed to $3.6M in Q3 2025 from $14.2M in Q3 2024.","Raised $327.8M in upsized IPO at $15.00 per share in September 2025.","Plans to initiate Phase 3 schizophrenia trial with ~460 patients in Q1 2026, topline expected H2 2027.","Appointed William Kane and Rekha Hemrajani to Board, James Rawls as SVP of Regulatory Affairs.","Cash position of $314.5M expected to fund operations into Q2 2028."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-268154","json":"https://secwatch.observer/filing/0001193125-25-268154.json","markdown":"https://secwatch.observer/filing/0001193125-25-268154.md","text":"https://secwatch.observer/filing/0001193125-25-268154.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1691082/000119312525268154/0001193125-25-268154-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1691082/000119312525268154/d84790d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud","generated_at":"2026-05-16T23:48:42.069747+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}